149 Aufrufe 149 0 Kommentare 0 Kommentare

    LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions - Seite 2

    Forward-Looking Statement Disclaimer

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.

    The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.

    Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    For more information about LIXTE, contact: 

    info@lixte.com
    General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
    or
    PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
    Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962


     Seite 2 von 2





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions - Seite 2 BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) - LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of …